Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • B-CELL  (1)
  • HUMAN GASTRIC CARCINOMAS  (1)
  • 1
    Keywords: CANCER ; EXPRESSION ; tumor ; human ; NEW-YORK ; ENZYMES ; PROTEIN ; PROTEINS ; TUMORS ; RELEASE ; PATIENT ; RESPONSES ; MESSENGER-RNA EXPRESSION ; ANTIGEN ; T cell ; T-CELL ; antibodies ; TARGET ; ASSAY ; poly(ADP-ribose) polymerase ; COLON-CANCER ; CD8(+) ; ELISPOT ; IMMUNE-RESPONSE ; IMMUNOTHERAPY ; DOMAINS ; protein expression ; ONCOLOGY ; RECOMBINANT ; humoral immune response ; SEREX ; LEVEL ; biomarker ; methods ; ASSAYS ; TELOMERASE ACTIVITY ; USA ; B-CELL ; immunology ; quantitative ; ANTIBODY-RESPONSE ; epitope mapping ; HUMAN AUTOANTIBODIES ; HUMAN GASTRIC CARCINOMAS ; POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE ; REPEAT-BINDING FACTOR-1 ; STERILE ALPHA-MOTIF ; telomerase-interacting proteins
    Abstract: Purpose Tankyrases 1 and 2 are telomere-associated poly(ADP-ribose) polymerases (PARP) that can positively regulate telomere elongation and interact with multiple cellular proteins. Recent reports implicated tankyrases as tumor antigens and potential targets of anticancer treatment. We examined expression of tankyrases in colon tumors and immune response to these enzymes in patients with different types of cancer. Methods mRNA and protein expression was evaluated by quantitative real-time RT-PCR and Western blotting, respectively. Humoral immune response to recombinant tankyrases was investigated by modified enzyme-linked immunoassays. Cellular immune response was analysed by ELISPOT and Cr-51 release assays. Results We found that both mRNA and protein levels of tankyrase 2 (TNKL) are upregulated in colon tumors. In contrast, protein level of tankyrase 1 (TNKS) is downregulated, while mRNA level shows variable changes. More than a quarter of colon cancer patients develop humoral immune response to at least one of the two tankyrases. In this study we mapped common and unique B-cell epitopes located in different domains of the two proteins. Additionally, we present evidence for T-cell responses both to epitopes that are unique for TNKL and to those shared between TNKL and TNKS. Conclusion Our study favors a biomarker usage of antibody response to tankyrases. Spontaneous CD8(+) T-cell responses to these enzymes are rare and further investigation is needed to evaluate tankyrases as potential targets for cancer immunotherapy
    Type of Publication: Journal article published
    PubMed ID: 18026951
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...